In Aβ-positive participants who were CU with or without SCD, NPS measures (i.e., MBI-C) were associated with early-stage AD Braak region tau-PET tracer binding and higher CSF p-tau181 levels, while cognitive performance measures (i.e., ADAS-DR) were not linked to tau.136. This evidence concerns the gene MAPT and Alzheimer disease.